Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.40 |
| ▸ | FURIN | P09958 | 4/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24224636 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22138625 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL27197502 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25450085 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL16946352 | 1.00 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24476142 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128021 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22128022 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL32667737 | 0.99 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL21570028 | 0.94 | FAP (0.39) | FAPFURINMAP1LC3BHTTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562011-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | Zymeworks BC Inc. (CA) | 2025-06-04 | — | — | EP | disclosed |
| US-20250170266-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2025-05-29 | — | — | US | disclosed |
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2024-04-18 | — | — | US | disclosed |
| WO-2024020684-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2024-02-01 | — | — | WO | disclosed |
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | HURT CLARENCE (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2022126263-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2022-06-23 | — | — | WO | disclosed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | TP53, KLK3, HLA-A | FAP 478/4885FURIN 1131/4885MAP1LC3B 916/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | FAP 219/4885FURIN 58/4885MAP1LC3B 1100/4885 |
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | DHFR, RARS2, DPYD | FAP 3819/4885FURIN 1760/4885MAP1LC3B 4677/4885 |
| US-20250170266-A1 | IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF | PAICS, ENTPD5, PNP | FAP 1044/4885FURIN 3338/4885MAP1LC3B 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.